VVN461 is a first-in-class innovative non-steroidal anti-inflammatory eye drop independently developed by Vivo Biopharm. It demonstrated excellent anti-inflammatory effects in this clinical trial. Compared with the positive control 1% prednisolone acetate eye drops, the two dose groups achieved statistical significance of non-inferiority to the control in both the primary efficacy endpoint and the secondary endpoint.
Previously, on December 3, 2024, VVN461 achieved the primary sri lanka telegram data and secondary endpoints in a Phase II clinical trial in the United States for the treatment of postoperative inflammation after cataract surgery, demonstrating excellent anti-inflammatory effects in the clinic. Both dose groups achieved statistical significance in all primary and secondary endpoints compared with the vehicle control.
Arthrosi's innovative gout drug AR882 achieved a patient enrollment rate of over 50% in the pivotal Phase III REDUCE 2 trial
San Diego, California, USA - On December 18, 2024, Arthrosi Therapeutics, Inc. " Arthros " , a late-stage clinical-stage biotechnology company co-invested and incubated by Via Biotech, is focused on developing a potential best-in-class, highly effective and selective new generation of URAT1 inhibitors to reduce serum uric acid sUA levels in gout patients, reduce gout attacks and tophi symptoms. The company announced that more than 50% of patients have been enrolled in the pivotal Phase III REDUCE 2 trial of its innovative gout drug AR882, which aims to evaluate the efficacy of AR882 in reducing sUA levels in gout patients.